Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Hose

Showing results (121-130 of 189) with videos related to

Pageof 19
Sort By:
Blood Advances|November 12, 2021
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myelomaJacob Stroh, Anja Seckinger, Michael Heider, et al.
Blood|February 12, 2011
Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)Tilmann Bochtler, Ute Hegenbart, Christiane Heiss, et al.
Frontiers in Immunology|May 9, 2024
Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibodyAnja Seckinger, Vanessa Buatois, Valéry Moine, et al.
International Journal of Cancer|March 21, 2008
Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myelomaJens Hillengass, Christian M Zechmann, Andreas Nadler, et al.
Oncotarget|November 22, 2017
Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trialMichael Schmitt, Angela G Hückelhoven, Michael Hundemer, et al.
Life Sciences|July 11, 2019
Pacemaker cell characteristics of differentiated and HCN4-transduced human mesenchymal stem cellsFabrice F Darche, Rasmus Rivinius, Eva Köllensperger, et al.
Blood Cancer Journal|April 10, 2019
Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trialKatja C Weisel, Christof Scheid, Manola Zago, et al.
Oncogene|March 1, 2005
Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cellsKarène Mahtouk, Dirk Hose, Thierry Rème, et al.
Blood|February 29, 2020
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuriaChristoph R Kimmich, Tobias Terzer, Axel Benner, et al.
Haematologica|May 20, 2017
Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow upUte Hegenbart, Tilmann Bochtler, Axel Benner, et al.
Pageof 19

Showing results (121-130 of 189) with videos related to

Sort By:
Pageof 19
Blood Advances|November 12, 2021
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myelomaJacob Stroh, Anja Seckinger, Michael Heider, et al.
Blood|February 12, 2011
Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)Tilmann Bochtler, Ute Hegenbart, Christiane Heiss, et al.
Frontiers in Immunology|May 9, 2024
Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibodyAnja Seckinger, Vanessa Buatois, Valéry Moine, et al.
International Journal of Cancer|March 21, 2008
Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myelomaJens Hillengass, Christian M Zechmann, Andreas Nadler, et al.
Oncotarget|November 22, 2017
Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trialMichael Schmitt, Angela G Hückelhoven, Michael Hundemer, et al.
Life Sciences|July 11, 2019
Pacemaker cell characteristics of differentiated and HCN4-transduced human mesenchymal stem cellsFabrice F Darche, Rasmus Rivinius, Eva Köllensperger, et al.
Blood Cancer Journal|April 10, 2019
Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trialKatja C Weisel, Christof Scheid, Manola Zago, et al.
Oncogene|March 1, 2005
Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cellsKarène Mahtouk, Dirk Hose, Thierry Rème, et al.
Blood|February 29, 2020
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuriaChristoph R Kimmich, Tobias Terzer, Axel Benner, et al.
Haematologica|May 20, 2017
Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow upUte Hegenbart, Tilmann Bochtler, Axel Benner, et al.
Pageof 19